SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the...
SIOUX FALLS, S.D., Feb. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the...
SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a...
SIOUX FALLS, S.D., Jan. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a...
First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human...
SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage...
Funding will support development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and...
Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors...
SIOUX FALLS, S.D., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a...
SIOUX FALLS, S.D., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), today...
Australian Human Research Ethics Committee (HREC) grants approval for SAB to begin first-in-human Phase 1...
SIOUX FALLS, S.D., Oct. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage...
Funding to support clinical advancement of SAB-142, a potential disease-modifying treatment Financing led by...
SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a...
SAB highlights results from GLP toxicology study confirming SAB-142's mechanism of action at the 23rd...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads